

**BMS TYK2 inhibitor**


FIC, oral, allosteric TYK2 inhibitor  
 FDA-approved for plaque psoriasis  
 opt. + SBDD of in-house phenotypic HTS hit  
 deucravacitinib (BMS-986165, SOTYKTU®)  
**BRISTOL MYERS SQUIBB, NY**

**Mirati/Array/Pfizer KRAS<sup>G12D</sup> inhibitor**


oral, BID, reversible KRAS<sup>G12D</sup> inhibitor  
 entering Ph. I/II for KRAS<sup>G12D</sup>-mutated tumors  
 from SBDD of KRAS<sup>G12C</sup> inhibitor  
 MRTX1133  
**MIRATI THERAPEUTICS/PFIZER, CO (ARRAY)**

**Madrigal THRβ-selective agonist**


oral, QD THRβ-selective agonist  
 Ph. III for NASH  
 opt. of triiodothyronine  
 resmetirom (MGL-3196)  
**MADRIGAL PHARMACEUTICALS, PA**

**GBT/Pfizer HbS polymerization inhibitor**


FIC, oral, QD, reversible covalent HbS pol. inhibitor  
 accelerated approval in SCD  
 opt. + SBDD of natural product (5HMF) analogs  
 voxelotor (GBT440, OXBRYTA®)  
**GLOBAL BLOOD THERAPEUTICS, CA/PFIZER, NY**

**Myokardia/BMS cardiac myosin inhibitor**


FIC, oral, QD, cardiac myosin inhibitor  
 FDA-approved for obstructive HCM  
 opt. of HTS hit for sarcomere activity inhibition  
 mavacamten (MYK461, CAMZYOS®)  
**MYOKARDIA, CA/BRISTOL MYERS SQUIBB, NY**

**Kura Oncology menin-MLL1 inhibitor**


oral, QD menin-MLL1 inhibitor  
 Ph. I/II for leukemia  
 from HTS and SBDD  
 ziftomenib (KO-539)  
**KURA ONCOLOGY/UMICH-GREMBECKA LAB**

**LEO Pharma IL-17A modulator**


oral, allosteric, IL-17A inactivator prodrug  
 Ph. I for psoriasis  
 SBDD from known compound  
 LPO200  
**LEO PHARMA, BALLERUP, DK**

**YourChoice/UMN RAR-α antagonist**

oral, non-hormonal male contraceptive  
 oral efficacy (99%) in preclinical model  
 SBDD from retinoic acid  
 YCT529  
**YOURCHOICE THERAPEUTICS/UMN-GEORG LAB**

**Cerevel/Pfizer M4 PAM**

oral, QD M4 positive allosteric modulator  
 Ph. II for schizophrenia  
 discovery not disclosed  
 emraclidine (CVL-231)  
**CEREVEL THERAPEUTICS, CAMBRIDGE, MA**

**ChemoCentryx C5aR antagonist**

FIC, oral, QD C5aR antagonist  
 FDA-approved as adjunctive treatment for AAV  
 discovery not disclosed  
 avacopan (CCX-168, TAVNEOS®)  
**CHEMOCENTRYX, CA/AMGEN INC., CA**